The Monash Prostate Cancer Registry, collects all prostate cancer diagnoses from
The Alfred,
Cabrini, and Traralgon hospitals, also from the Austin and soon also Moorabbin Radiation Oncology, Royal Melbourne and the Peter MacCallum Cancer Centre. This represents information on about one third of diagnoses in the state; including demographics, stage, histology, treatments and outcomes. The pilot registry is supported by a $600,000 Cancer Australia/NHMRC/PCFA grant, and is managed by Associate Professor Jeremy Millar, Dr Sue Evans and Professor Mark Frydenberg
Associate Professor Jeremy Millar is the Director of
Radiation Oncology at Alfred Health, which includes one of Melbourne’s premier centres the
William Buckland Radiotherapy Centre. Associate Professor Millar leads the Radiation Oncology Genito-Urinary cancer group at Alfred Health and as part of this, developed and leads a large prostate brachytherapy program at the
Melbourne Prostate Institute, as well as an External Beam Radiotherapy Service. Associate Professor Millar provides a specialist understanding of the effects of radiation on normal tissues and urological malignancies, as well as an academic and research interest in prostate cancer.
Dr Sue Evans is a leading Investigator on a research program within the
School of Public Health and Preventive Medicine, Monash University focusing on developing clinical registry science.
Professor Mark Frydenberg is one of Australia’s most respected authorities in urological oncology. He is Head of the
Department of Urology at Monash Medical Centre, Chairman of the Urologic Oncology Special Advisory Group of the
Urological Society of Australia and New Zealand and has a clinical associate professorship in the
Monash University Departments of Surgery. As well as his clinical expertise, Professor Frydenberg is a major contributor to patient education and supporter of Men’s Health through
Andrology Australia.
Professor Gail Risbridger of Monash University is one of Australia’s leading prostate cancer researchers, with particular interest in the biology of stromal-epithelial cell interactions in normal and tumour tissue using tissue recombination, animal and human specimens. Professor Risbridger pioneered the use of stem cells for recombination studies combining stem cell biology with endocrinology
Monash University’s Eastern Health Clinical School (ECRU) Oncology Clinical Trials is based at Box Hill Hospital Campus, Monash University. The unit has both Investigator and Pharmaceutical clinical trials in a variety of including prostate cancer trials, which is currently run by
Dr Phillip Parente, an Epworth Eastern Consultant Oncologist. Studies are mostly Phase 2 or Phase 3 large collaborative studies.